MediWound Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

MediWound wird ein Gewinn- und Umsatzwachstum von 60.2% bzw. 43.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 58.7% pro Jahr wachsen soll.

Wichtige Informationen

60.2%

Wachstumsrate der Gewinne

58.7%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.9%
Wachstumsrate der Einnahmen	43.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	26 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report

Jun 01

Recent updates

MediWound Is A Healthy Investment

Oct 29

Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher

Jul 23

Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report

Jun 01

Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%

May 07

We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely

Feb 28

Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking

Feb 01

MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up

Dec 18

MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Sep 29

MediWound's NexoBrid for thermal burns in children gets EMA review

Sep 20

Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates

Aug 11

MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M

Aug 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:MDWD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	39	-13	N/A	N/A	3
12/31/2025	27	-22	N/A	N/A	4
12/31/2024	20	-33	N/A	N/A	1
9/30/2024	20	-28	-22	-15	N/A
6/30/2024	20	-20	-22	-14	N/A
3/31/2024	20	-13	-22	-16	N/A
12/31/2023	19	-7	-17	-10	N/A
9/30/2023	25	-12	-10	-6	N/A
6/30/2023	26	-14	-10	-7	N/A
3/31/2023	26	-20	-9	-7	N/A
12/31/2022	26	-20	-12	-12	N/A
9/30/2022	20	-16	-17	-16	N/A
6/30/2022	21	-15	-15	-14	N/A
3/31/2022	22	-14	-10	-10	N/A
12/31/2021	24	-14	-9	-9	N/A
9/30/2021	25	-11	-11	-10	N/A
6/30/2021	25	-10	-7	-6	N/A
3/31/2021	23	-10	-9	-8	N/A
12/31/2020	22	-9	-8	-7	N/A
9/30/2020	21	-11	-7	-6	N/A
6/30/2020	19	-12	-12	-12	N/A
3/31/2020	36	4	8	8	N/A
12/31/2019	32	2	7	8	N/A
9/30/2019	27	12	8	9	N/A
6/30/2019	23	12	11	12	N/A
3/31/2019	3	-5	-12	-11	N/A
12/31/2018	3	-6	-13	-12	N/A
9/30/2018	3	-14	-15	-15	N/A
6/30/2018	3	-14	N/A	-16	N/A
3/31/2018	2	-15	N/A	-15	N/A
12/31/2017	2	-15	N/A	-16	N/A
9/30/2017	2	-14	N/A	-16	N/A
6/30/2017	2	-16	N/A	-18	N/A
3/31/2017	2	-19	N/A	-17	N/A
12/31/2016	2	-19	N/A	-16	N/A
9/30/2016	1	-25	N/A	-17	N/A
6/30/2016	1	-23	N/A	-18	N/A
3/31/2016	1	-19	N/A	-19	N/A
12/31/2015	1	-22	N/A	-20	N/A
9/30/2015	0	-21	N/A	-19	N/A
6/30/2015	0	-22	N/A	-18	N/A
3/31/2015	0	-24	N/A	-18	N/A
12/31/2014	0	-19	N/A	-16	N/A
9/30/2014	0	-12	N/A	-15	N/A
6/30/2014	0	-10	N/A	-13	N/A
3/31/2014	0	-7	N/A	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MDWD wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).

Ertrag vs. Markt: MDWD wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: MDWD wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: MDWDDie Einnahmen des Unternehmens (43.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: MDWDDie Einnahmen des Unternehmens (43.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MDWD in 3 Jahren voraussichtlich hoch sein wird

MediWound Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

MediWound Ltd. Revises Revenue Guidance for 2024

Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report

Consensus EPS estimates fall by 25%, revenue upgraded

Consensus EPS estimates upgraded to US$0.75 loss

Price target decreased by 20% to US$27.25

Consensus revenue estimates fall by 12%

Recent updates

MediWound Ltd. Revises Revenue Guidance for 2024

MediWound Ltd. to Report Q3, 2024 Results on Nov 26, 2024

MediWound Is A Healthy Investment

MediWound Ltd. Announces Phase II Head-To-Head Study Evaluating EscharEx®? vs. Collagenase in Patients with Venous Leg Ulcers

MediWound Ltd. Announces Positive Results from the U.S. NexoBrid Expanded Access Protocol (NEXT)

MediWound Ltd. to Report Q2, 2024 Results on Aug 14, 2024

MediWound Ltd. Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher

MediWound Ltd. announced that it expects to receive $24.999994 million in funding from Mölnlycke Health Care AB and other investors

Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report

MediWound Ltd., Annual General Meeting, Jul 09, 2024

MediWound Ltd. to Report Q1, 2024 Results on May 29, 2024

Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%

Consensus EPS estimates fall by 25%, revenue upgraded

Full year 2023 earnings released: US$0.74 loss per share (vs US$3.93 loss in FY 2022)

MediWound Ltd. to Report Q4, 2023 Results on Mar 21, 2024

We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely

Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study

Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking

Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns

Mediwound Ltd. Announces Publication of Escharex Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up

Third quarter 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates upgraded to US$0.75 loss

MediWound Ltd. Appoints Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, Effective December 1, 2023

MediWound Ltd. to Report Q3, 2023 Results on Nov 21, 2023

MediWound Ltd Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

MediWound Ltd. Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army

New major risk - Shareholder dilution

MediWound Ltd. Announces U.S. Commercial Availability of NexoBrid®? for the Treatment of Severe Thermal Burns in Adults

High number of new and inexperienced directors

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 20% to US$27.25

MediWound Ltd. to Report Q2, 2023 Results on Aug 15, 2023

MediWound Ltd. Announces Commercial Launch of NexoBrid®? in Japan

Mediwound Ltd. Announces Positive Results in Its U.S. Phase I/Ii Study of Mw005 for the Treatment of Basal Cell Carcinoma

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design

Consensus revenue estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

MediWound Ltd. to Report Q1, 2023 Results on May 30, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus estimates of losses per share improve by 10%

MediWound Ltd. Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

Price target decreased to US$43.50

MediWound Announces Positive Results in U.S. Phase I/II Study of Mw005 for the Treatment of Basal Cell Carcinoma

MediWound Ltd Gains Marketing Approval of NexoBrid® in India

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

MediWound Ltd. to Report Q3, 2022 Results on Nov 15, 2022

High number of new directors

High number of new directors

MediWound Ltd. Announces Formation of Strategic Advisory Board

MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022

Price target increased to US$7.20

MediWound Ltd. Announces European Medicines Agency Validates for Review the Type Ii Variation

MediWound's NexoBrid for thermal burns in children gets EMA review

Consensus revenue estimates fall by 14%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates

Mediwound Ltd. Announces Management Changes

Price target increased to US$6.90

MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M

MediWound Announces U.S. FDA Acceptance of Biologics License Application for Nexobrid for the Treatment of Severe Thermal Burns

MediWound refiling for NexoBrid to treat severe thermal burns gets FDA review

MediWound Ltd. to Report Q2, 2022 Results on Aug 09, 2022

MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

MediWound Ltd. Announces Positive Results from Its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers

MediWound adds 13% after favorable data for ulcer candidate